-- 1 of 33 -- th January 21, 2026 -- 2 of 33 -- Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3 -- 3 of 33 -- REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications Immunology INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Neuroscience PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Infectious Diseases INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Cardiovascular/ Metabolism/Other IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc. Oncology UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Pulmonary Hypertension Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Global Public Health Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4 -- 4 of 33 -- CEO Remarks Sales performance and earnings review Cash position and guidance update Q&A Agenda 5 John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech 1 2 3 4 -- 5 of 33 -- Joaquin Duato Chairman and Chief Executive Officer -- 6 of 33 -- 2025 was a catapult year full-year operational sales growth platforms with at least $1 billion annual revenue 28 SHOCKWAVE CARVYKTI each surpass $1 billion in annual sales for first time 5.3%1,2 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (620) basis point headwind from STELARA 7 -- 7 of 33 -- Innovative Medicine 1,2 full-year operational sales growth 2025-at-a-glance ~$60 billion annual sales 13 brands growing double digits 51 approvals and 32 filings across major markets3 17 key studies with positive readouts 11 new phase 3 programs initiated 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (1,040) basis point headwind from STELARA 3 Includes the U.S., EU, Japan, and China 8 -- 8 of 33 -- Innovative Medicine Oncology Neuroscience Immunology 9 -- 9 of 33 -- MedTech 1 full-year operational sales growth 2025-at-a-glance ~$34 billion annual sales 15 launches in major markets2 40+ regulatory approvals in major markets2 60+ active clinical trials 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes the U.S. and EU 10 -- 10 of 33 -- MedTech Addressing one of the largest unmet needs in healthcare Advancing the science of surgery and pioneering what's next Developing transformational innovations to improve the health of patients’ eyes Cardiovascular Surgery Vision MedTech Innovation: MedTech Innovation: MedTech Innovation: VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee Impella® Heart Pump Technology MONARCH Platform 11 -- 11 of 33 -- Note: related to sales; excludes the impact of translational currency 12 -- 12 of 33 -- Darren Snellgrove Vice President, Investor Relations -- 13 of 33 -- % Change Q4 2024 Q4 2025 Regional sales results Operational1 Reported 7.5% 7.5% $13.2 $14.2 U.S. 5.2 13.8 4.9 5.6 Europe 11.0 12.0 1.1 1.3 Western Hemisphere (ex U.S.) 7.2 7.4 3.3 3.5 Asia-Pacific, Africa 6.6 11.3 9.3 10.4 International 7.1% 9.1% $22.5 $24.6 Worldwide (WW) Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 4th Quarter 2025 sales 14 -- 14 of 33 -- $24.6 $22.5 $6.0 $4.9 20.6%; 15.2%1 $2.46 $2.043 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS2 9.1%; 7.1%1 GAAP earnings $5.1 $3.4 21.5% Q4 2025 Q4 2024 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 3 Includes $(0.22) due to acquired IPR&D charges related to V-wave acquisition 4th Quarter 2025 financial highlights GAAP EPS 15 Q4 2025 Q4 2024 Q4 2025 Q4 2024 Q4 2025 Q4 2024 Q4 2025 Q4 2024 $2.10 $1.413 49.1% 48.9% -- 15 of 33 -- % Change 2024 2025 Regional sales results Operational1 Reported 6.9% 6.9% $50.3 $53.8 U.S. 2.4 6.5 20.2 21.5 Europe 8.4 3.4 4.7 4.9 Western Hemisphere (ex U.S.) 3.1 3.2 13.6 14.0 Asia-Pacific, Africa 3.4 5.0 38.5 40.4 International 5.3% 6.0% $88.8 $94.2 Worldwide (WW) Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded Full-year 2025 sales 16 -- 16 of 33 -- $26.2 $24.2 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 3 Includes $(0.67) due to acquired IPR&D charges on various transactions throughout the year 8.1%; 6.0%1 $10.79 $9.983 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS2 6.0%; 5.3%1 90.6% $26.8 $14.1 8.1% 90.5% $11.03 $5.793 2025 2024 2025 2024 2025 2024 $94.2 $88.8 2025 2024 2025 2024 Full-year 2025 financial highlights GAAP EPS 17 GAAP earnings -- 17 of 33 -- Immunology $3,860 Infectious Diseases $807 Neuroscience $2,115 Oncology $6,861 CVM/Other $936 PH $1,184 ■ Reported growth ■ Operational growth1 $15,763 10.0%, 7.9% WW sales $MM Key drivers of operational performance1 • DARZALEX increase primarily driven by continued strong share gains as well as inventory dynamics and market growth • ERLEADA growth driven by market growth and continued share gains, partially offset by the impact of Part D redesign • CARVYKTI increase driven by continued share gains and site expansion • TECVAYLI and TALVEY growth driven by continued share gains • RYBREVANT/LAZCLUZE increase driven by ongoing launch and share gains • Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to the impact of Part D redesign and competitive pressures Oncology • TREMFYA increase due to share gains and market growth • SIMPONI/SIMPONI ARIA growth driven primarily by market growth, partially offset by share decline • REMICADE increase due to favorable patient mix and market growth, partially offset by biosimilar competition • STELARA decline driven by the impact of biosimilar competition and Part D redesign Immunology • SPRAVATO growth driven by continued increased physician and patient demand • CAPLYTA acquired April 2, 2025 • INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the impact of Part D redesign Neuroscience • UPTRAVI increase driven by inventory dynamics and market growth, partially offset by the impact of Part D redesign • OPSUMIT/OPSYNVI growth driven by share gains, market growth, and favorable patient mix, partially offset by the impact of Part D redesign Pulmonary Hypertension (PH) • Declines across the portfolio partially offset by EDURANT growth Infectious Diseases • XARELTO growth driven by the impact of Part D redesign and market growth, partially offset by continued share loss Cardiovascular / Metabolism / Other (CVM/Other) Adjusted operational sales2: WW: 6.2%, U.S. 5.1%, Int’l 8.0% Innovative Medicine highlights – 4th quarter 2025 WW 10.0%, U.S. 7.9%, Int’l 13.4% Reported: WW 7.9%, U.S. 7.9%, Int’l 7.9% Operational1: (2.2)%, (2.9)% 8.4%, 7.4% 24.8%, 21.9% 4.3%, (0.4)% (8.9)%, (10.3)% Strong operational growth1 of 7.9% driven primarily by Oncology and Neuroscience 19.1%, 17.9% 18 Stelara impacted results1 by ~(1,110) basis points 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded -- 18 of 33 -- Key drivers of operational performance1 • Electrophysiology: Growth driven by procedure growth, commercial execution, and new product performance (VARIPULSE, TRUPULSE, NUVISION), partially offset by competitive pressures in PFA • Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP • Shockwave: Double digit growth driven by Coronary and Peripheral portfolios and new product launches (JAVELIN & E8) Cardiovascular All platforms impacted by revenue disruption from the previously announced Orthopaedics transformation, which is now substantially complete: • Hips: Increase driven by new product launches (EMPHASYS) • Trauma: Growth driven by recently launched products (VOLT) and commercial execution, partially offset by trade inventory dynamics and volume-based procurement (VBP) in China • Knees: Increase driven by commercial execution and strength of the ATTUNE portfolio, partially offset by trade inventory dynamics and VBP in China • Spine, Sports & Other: Growth driven by spine innovations (TriAltis) and commercial execution, partially offset by competitive pressures and price pressures in the U.S. Early Interventional segment • Spine: ~ +3% WW, ~ +5% U.S., ~ -1% Int’l Orthopaedics • Advanced: • Biosurgery: ~ +5% growth driven by continued strength of the portfolio and commercial execution, partially offset by VBP in China • Endocutters: ~ -3% due to VBP in China and competitive pressures • Energy: ~ Flat due to competitive pressures, Harmonic market decline in the U.S., and VBP in China, offset by OUS growth • General: Growth primarily due to technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) coupled with commercial execution Surgery • Contact Lenses/Other: Increase driven by market growth, strong performance of the ACUVUE OASYS 1-Day family, and continued strategic price actions • Surgical: Growth driven by strength of recent product innovations (TECNIS PureSee, TECNIS Odyssey, TECNIS Eyhance), robust demand for premium IOLs, and strong commercial execution Vision Adjusted operational sales2: WW 5.9%, U.S. 6.7%, Int’l 5.1% Orthopaedics $2,438 Surgery $2,644 Vision $1,420 Cardiovascular $2,299 ■ Reported growth ■ Operational growth1 $8,801 7.5%, 5.8% WW sales $MM Strong operational growth1 of 5.8% due to commercial execution and innovation WW 7.5%, U.S. 6.6%, Int’l 8.5% Reported: WW 5.8%, U.S. 6.6%, Int’l 4.9% Operational1: 11.5%, 10.1% 8.9%, 6.8% 5.3%, 3.5% 5.5%, 3.7% MedTech highlights – 4th quarter 2025 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 19 -- 19 of 33 -- % Increase (Decrease) 2024 2025 % to Sales Amount % to Sales Amount 9.1 100.0 $22,520 100.0 $24,564 Sales to customers 11.8 31.6 7,128 32.4 7,968 Cost of products sold 7.8 68.4 15,392 67.6 16,596 Gross Profit 4.6 28.6 6,453 27.5 6,753 Selling, marketing and administrative expenses (19.7) 23.5 5,298 17.3 4,252 Research and development expense 0.1 17 0.3 81 In-process research and development impairments (0.6) (144) (0.1) (23) Interest (income) expense, net (0.7) (161) 2.0 483 Other (income) expense, net 0.2 42 0.4 84 Restructuring 27.8 17.3 3,887 20.2 4,966 Earnings before provision for taxes on income (132.9) 2.1 456 (0.6) (150) (Benefit from)/Provision for taxes on income 49.1 15.2 $3,431 20.8 $5,116 Net Earnings - 48.9 $1.41 $2.10 Net earnings per share (Diluted) 2,427.1 2,439.0 Average shares outstanding (Diluted) 11.7% (3.0)% Effective tax rate . Adjusted earnings before provision for taxes and net earnings1 30.0 24.1 $5,421 28.7 $7,046 Earnings before provision for taxes on income 21.5 22.0 $4,946 24.5 $6,009 Net earnings 20.6 $2.04 $2.46 Net earnings per share (Diluted) 8.8% 14.7% Effective tax rate 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollar and shares in millions except per share figures) 20 4th Quarter 2025 Condensed consolidated statement of earnings -- 20 of 33 -- % Increase (Decrease) 2024 2025 Innovative Medicine % to Sales Amount % to Sales Amount 10.0 100.0 $14,332 100.0 $15,763 Sales to customers 15.3 19.7 2,829 20.7 3,261 Cost of products sold 8.7 80.3 $11,503 79.3 $12,502 Gross Profit 4.3 23.1 3,312 21.9 3,456 Selling, marketing and administrative expenses (6.1) 25.8 3,692 22.0 3,466 Research and development expense (1.1) (158) (0.9) (135) Other segment items 1 22.7 32.5 $4,657 36.3 $5,715 Adjusted segment income before tax 2 (Unaudited; Dollar in millions) Adjusted earnings before provision for taxes on income by segment 21 % Increase (Decrease) 2024 2025 MedTech % to Sales Amount % to Sales Amount 7.5 100.0 $8,188 100.0 $8,801 Sales to customers 17.3 35.8 2,928 39.0 3,435 Cost of products sold 2.0 64.2 $5,260 61.0 $5,366 Gross Profit 7.2 34.6 2,832 34.5 3,035 Selling, marketing and administrative expenses (50.1) 19.2 1,575 8.9 786 Research and development expense 3 (0.4) (33) 0.2 10 Other segment items 1 73.3 10.8 $886 17.4 $1,535 Adjusted segment income before tax 2 % Increase (Decrease) 2024 2025 Enterprise % to Sales Amount % to Sales Amount 30.0 24.1 $5,421 28.7 $7,046 Adjusted income before tax 2 4th Quarter 2025 1 Other segment items for each reportable segment include charges related to other income and expenses 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 3 Includes acquired IPR&D for V-Wave in Q4 2024, totaling $540 Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website -- 21 of 33 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 22 of 33 -- Capital allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Q4 2025 Dollars in billions ~$20 Cash and marketable securities ~($48) Debt ~($28) Net debt ~$20 Free cash flow1,2 Full-year 2025: $14.7B invested in R&D $12.4B in dividends paid to shareholders Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment 2 Estimated as of January 21, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings Note: Values may be rounded Capital allocation strategy 23 -- 23 of 33 -- Operational2 sales guidance of 6.2% and adjusted operational EPS2,4 at 5.5% (midpoints) Comments January 2026 Midpoint of 5.9% 5.4% - 6.4% Adjusted operational sales1,2 Midpoint of $100.0B or 6.2% $99.5B - $100.5B 5.7% - 6.7% Operational sales2 Midpoint of $100.5B or 6.7% FX impact of $0.5B or 0.5% $100.0B - $101.0B 6.2% - 7.2% Estimated reported sales 3 Net impact of operating efficiencies Increase of at least 50 bps Adjusted pre-tax operating margin4,5 Relatively flat to 2025 levels $1.0 - $1.2 billion Net other income4 Higher average debt levels $300 - $400 million Net interest expense / (income) Change in income mix 17.5% - 18.5% Effective tax rate4 Midpoint of $11.38 or 5.5% $11.28 - $11.48 4.5% - 6.5% Adjusted EPS (operational)2,4 Midpoint of $11.53 or 6.9% FX impact of $0.15 or 1.4% $11.43 - $11.63 5.9% - 7.9% Adjusted EPS (reported)3,4 Consistent with Q4 2025 shares outstanding ~2,440 million Average shares outstanding6 2026 P&L guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Euro Average Rate: January 2026 = $1.17; Euro Spot Rate: January 2026 = $1.17 6 Full-year 2026 projected average shares outstanding (diluted) Note: Values may be rounded 24 -- 24 of 33 -- Innovative Medicine • Expect more pronounced impact from newly launched products as the year progresses • Regarding STELARA, HUMIRA erosion curve remains the best proxy2 • Anticipate generic competition for OPSUMIT (second half in U.S.) and SIMPONI (first half in EU; potentially second half in U.S.) • Expect impact of voluntary agreement with the U.S. government to be evenly distributed throughout the year • Expect continued acceleration of newly launched products as the year progresses with normalized seasonality • Surgery transformation topline sales headwind expected to accelerate throughout the year • Anticipate additional rounds of VBP in China throughout the year • The impact of tariffs assumed to be consistent throughout the year 2026 Phasing Considerations MedTech • Expect heavy investment in Q1 2026 compared to the rest of the year • One-time items impacting EPS last year: • Impact of Stelara erosion in Q1 2025 was less pronounced • Intra-Cellular benefit laps in Q2 • Impact of tariffs laps in Q4 • Anticipate higher earnings per share growth in the second half of the year compared to the first half P&L 25 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 STELARA Year 2 erosion curve assumes best proxy with HUMIRA Year 3 erosion curve Anticipate fairly consistent operational1 sales growth in the first and second half; 53rd week impacts the second half -- 25 of 33 -- Innovative Medicine Anticipated 2026 milestones1 driving long-term value creation MedTech 26 ICOTYDE in PsO TECVAYLI + DARZALEX in RRMM TREMFYA in PsA SD TECVAYLI in RRMM INLEXZO in HR NMIBC nipocalimab in WAIHA and SLE CAPLYTA in bipolar mania JNJ-4804 ERLEADA in LPC & HRPC OTTAVA ETHIZIA STSF Dual Energy Catheter C2 Aero Catheters TECNIS PureSee IOL ATTUNE Hinge VOLT MONARCH Urology 1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches PsO: Psoriasis; RRMM: Relapsed/refractory multiple myeloma; PsA SD: Psoriatic arthritis structural damage; HR NMIBC: High-risk non-muscle invasive bladder cancer; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; LPC: Localized prostate cancer; HRPC: High-risk prostate cancer; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens -- 26 of 33 -- Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Darren Snellgrove Vice President, Investor Relations Jennifer Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech -- 27 of 33 -- Slide footer goes here if required 28 -- 28 of 33 -- Immunology $15,728 Infectious Diseases $3,241 Neuroscience $7,837 Oncology $25,380 CVM/Other $3,778 PH $4,437 ■ Reported growth ■ Operational growth1 $60,401 6.0%, 5.3% WW sales $MM WW 6.0%, U.S. 7.0%, Int’l 4.6% Reported: WW 5.3%, U.S. 7.0%, Int’l 2.9% Operational1: Orthopaedics $9,258 Surgery $10,137 Vision $5,468 Cardiovascular $8,928 ■ Reported growth ■ Operational growth1 $33,792 6.1%, 5.4% WW sales $MM Innovative Medicine and MedTech FY 2025 Sales 6.1%, 6.0% 3.6%, 3.2% 22.1%, 20.9% (4.6)%, (6.5)% (11.8)%, (12.0)% Innovative Medicine 10.1%, 9.9% 29 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded Adjusted operational sales2: WW: 4.1%, U.S. 4.9%, Int’l 3.0% MedTech Adjusted operational sales2: WW 4.3%, U.S. 4.8%, Int’l 3.8% 15.8%, 15.2% 6.3%, 5.3% 1.1%, 0.3% 3.0%, 2.5% Strong full-year 2025 operational sales growth1 across Innovative Medicine and MedTech WW 6.1%, U.S. 6.6%, Int’l 5.5% Reported: WW 5.4%, U.S. 6.6%, Int’l 4.1% Operational1: -- 29 of 33 -- % Increase (Decrease) 2024 2025 % to Sales Amount % to Sales Amount 6.0 100.0 $88,821 100.0 $94,193 Sales to customers 10.1 30.9 27,471 32.1 30,256 Cost of products sold 4.2 69.1 61,350 67.9 63,937 Gross Profit 3.5 25.7 22,869 25.1 23,676 Selling, marketing and administrative expenses (14.9) 19.4 17,232 15.6 14,665 Research and development expense 0.2 211 0.1 81 In-process research and development impairments (0.6) (577) (0.1) (85) Interest (income) expense, net 5.3 4,694 (7.6) (7,209) Other (income) expense, net 0.3 234 0.2 228 Restructuring 95.2 18.8 16,687 34.6 32,581 Earnings before provision for taxes on income 120.4 3.0 2,621 6.1 5,777 Provision for taxes on income 90.6 15.8 $14,066 28.5 $26,804 Net Earnings - 90.5 $5.79 $11.03 Net earnings per share (Diluted) 2,429.4 2,429.4 Average shares outstanding (Diluted) 15.7% 17.7% Effective tax rate . Adjusted earnings before provision for taxes and net earnings1 9.3 32.6 $28,979 33.6 $31,681 Earnings before provision for taxes on income 8.1 27.3 $24,242 27.8 $26,215 Net earnings 8.1 $9.98 $10.79 Net earnings per share (Diluted) 16.3% 17.3% Effective tax rate 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollar and shares in millions except per share figures) 30 Full-year 2025 Condensed consolidated statement of earnings -- 30 of 33 -- % Increase (Decrease) 2024 2025 Innovative Medicine % to Sales Amount % to Sales Amount 6.0 100.0 $56,964 100.0 $60,401 Sales to customers 14.7 19.8 11,256 21.4 12,905 Cost of products sold 3.9 80.2 $45,708 78.6 $47,496 Gross Profit 4.3 19.1 10,906 18.8 11,375 Selling, marketing and administrative expenses (12.4) 23.7 13,504 19.6 11,827 Research and development expense 1 (2.0) (1,154) (1.2) (706) Other segment items 2 11.3 39.4 $22,452 41.4 $25,000 Adjusted segment income before tax 3 (Unaudited; Dollar in millions) Adjusted earnings before provision for taxes on income by segment 31 % Increase (Decrease) 2024 2025 MedTech % to Sales Amount % to Sales Amount 6.1 100.0 $31,857 100.0 $33,792 Sales to customers 12.3 34.9 11,122 37.0 12,491 Cost of products sold 2.7 65.1 $20,735 63.0 $21,301 Gross Profit 5.2 33.9 10,796 33.6 11,354 Selling, marketing and administrative expenses (18.6) 11.1 3,530 8.5 2,875 Research and development expense 4 (1.5) (487) (0.6) (210) Other segment items 2 5.6 21.6 $6,896 21.5 $7,282 Adjusted segment income before tax 3 % Increase (Decrease) 2024 2025 Enterprise % to Sales Amount % to Sales Amount 9.3 32.6 $28,979 33.6 $31,681 Adjusted income before tax 3 Full-year 2025 1 Includes acquired IPR&D for the global rights to the NM26 bispecific antibody in Q3 2024, totaling $1,250 4 Includes acquired IPR&D for V-Wave in Q4 2024, totaling $540 2 Other segment items for each reportable segment include charges related to other income and expenses Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website 3 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website -- 31 of 33 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II P US SIMPONI (golimumab) P US IMAAVY (nipocalimab ) US nipocalimab P US INLEXZO (gemcitabine intravesical delivery system) P AKEEGA (niraparib/abiraterone) P INLEXZO (gemcitabine delivery intravesical system) P EU Pediatric Ulcerative Colitis (PURSUIT 2) P EU Generalized Myasthenia Gravis (Vivacity MG3) Warm Autoimmune Hemolytic Anemia (ENERGY) Non Muscle Invasive Bladder Cancer (SunRISe-1) M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Non Muscle Invasive Bladder Cancer (SunRISe-1) STELARA (ustekinumab) P US SPRAVATO (esketamine) TREMFYA (guselkumab) P US AKEEGA (niraparib/abiraterone) P RYBREVANT / LAZCLUZE P RYBREVANT (amivantamab) P EU Pediatric Crohn's Disease (UNITI JR) Treatment Resistant Depression monotherapy (TRD4005) P EU Ulcerative Colitis Subcutaneous Induction (ASTRO) P EU M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Non Small Cell Lung Cancer (MARIPOSA Final OS) Head and Neck Cancer (ORIGAMI-4) P US TREMFYA (guselkumab) P US CAPLYTA (lumateperone) P US TREMFYA (guselkumab) P US TECVAYLI (teclistamab) P TREMFYA (guselkumab) P TALVEY + TECVAYLI P EU Ulcerative Colitis Subcutaneous Induction (ASTRO) Adjunctive Treatment for Major Depressive Disorder Psoriatic Arthritis Structural Damage (APEX) 0 Multiple Myeloma 1-3PLs (MajesTEC- 3) Ulcerative Colitis Subcutaneous Induction (ASTRO) Multiple Myeloma Relapsed/Refractory (RedirecTT-1) P US TREMFYA (guselkumab) P US DARZALEX (daratumumab) TREMFYA (guselkumab) P TREMFYA (guselkumab) P JNJ-4496 P EU Crohn's Disease Subcutaneous Induction (GRAVITI) P EU Smoldering Multiple Myeloma (AQUILA) P EU Pediatric Psoriasis (PROTOSTAR) Psoriatic Arthritis Structural Damage (APEX) Hematological Malignancies (LYM1001) P US TREMFYA (guselkumab) US DARZALEX (daratumumab) P US STELARA (ustekinumab) P TREMFYA (guselkumab) P JNJ-5322 Pediatric Psoriasis (PROTOSTAR) P EU Frontline multiple myeloma transplant ineligible (CEPHEUS) P EU Pediatric Ulcerative Colitis (UNIFI JR) Pediatric Psoriasis (PROTOSTAR) Multiple Myeloma (MMY1001) P US TREMFYA (guselkumab) P US INLEXZO (gemcitabine intravesical delivery system) P US STELARA (ustekinumab) P icotrokinra P RYBREVANT (amivantamab) Pediatric Juvenile Psoriatic Arthritis Non Muscle Invasive Bladder Cancer (SunRISe-1) Pediatric Crohn's Disease (UNITI JR) Psoriasis (ICONIC-LEAD) Colorectal Cancer (ORIGAMI-1 right- sided) P US TREMFYA (guselkumab) P US RYBREVANT (amivantamab) P US icotrokinra P icotrokinra P JNJ-8343 P EU Crohn's Disease (GALAXI) P EU Subcutaneous (PALOMA-3) P EU Psoriasis (ICONIC) Psoriasis (ICONIC-TOTAL) Prostate Cancer (PCR1001) TREMFYA (guselkumab) IMBRUVICA (ibrutinib) P icotrokinra JNJ-4804 Co-antibody Therapy P EU Ulcerative Colitis (QUASAR) P EU Frontline MCL (Triangle) Psoriasis (ICONIC-Advance1/2) Psoriatic Arthritis (AFFINITY) P US IMAAVY (nipocalimab ) P aticaprant P icotrokinra Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG) Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1) Ulcerative Colitis (ANTHEM) P US AKEEGA (niraparib/abiraterone) P RPGR Gene Therapy M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE) Retinitis Pigmentosa (LUMEOS) P TECVAYLI (teclistamab) Multiple Myeloma 1-3PLs (MajesTEC-3) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2025* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 26, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. = Achieved 1 In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investments. This information is as of January 21, 2026 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information. -- 32 of 33 -- POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II US TREMFYA (guselkumab) US nipocalimab US ERLEADA (apalutamide) icotrokinra ERLEADA (apalutamide) JNJ-4804 Co-antibody Therapy Psoriatic Arthritis Structural Damage (APEX) Warm Autoimmune Hemolytic Anemia (ENERGY) EU Localized Prostate Cancer (ATLAS) Psoriasis (ICONIC-ADVANCE 1&2 Update) Localized Prostate Cancer (ATLAS) Ulcerative Colitis (DUET-UC) US icotrokinra US CAPLYTA (lumateperone) US ERLEADA (apalutamide) icotrokinra ERLEADA (apalutamide) JNJ-4804 Co-antibody Therapy EU Psoriasis (ICONIC) Bipolar Mania EU High Risk Prostate Cancer (PROTEUS) Psoriasis (ICONIC-ASCEND) High Risk Prostate Cancer (PROTEUS) Crohn's Disease (DUET-CD) AKEEGA (niraparib/abiraterone) US bleximenib icotrokinra TALVEY (talquetamab) JNJ-4804 Co-antibody Therapy EU M1 Metastatic Castration- Sensitive Prostate Cancer (AMPLITUDE) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) Psoriatic Arthritis (ICONIC-PsA) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriatic Arthritis (AFFINITY) US DARZALEX (daratumumab) US TALVEY (talquetamab) icotrokinra TECVAYLI (teclistamab) nipocalimab Frontline multiple myeloma transplant ineligible (CEPHEUS) EU Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriasis (ICONIC-TOTAL Update) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC- 9) Systemic Lupus Erythematosus (JASMINE) US TECVAYLI (teclistamab) US TECVAYLI (teclistamab) CAPLYTA (lumateperone) INLEXZO (gemcitabine intravesical delivery system) bleximenib EU Multiple Myeloma 1-3PLs (MajesTEC-3) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) Bipolar Mania (ITI-007-452) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) TECVAYLI (teclistamab) JNJ-1887 sCD59 P EU Multiple Myeloma 1-3PLs (MajesTEC-3) Geographic Atrophy (PARASOL) US INLEXZO (gemcitabine intravesical delivery system) EU High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of "&Date&" to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. = Achieved 1 In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investments. This information is as of January 21, 2026 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information. -- 33 of 33 --